<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01555086</url>
  </required_header>
  <id_info>
    <org_study_id>AP 55/09</org_study_id>
    <secondary_id>DRKS00003256</secondary_id>
    <nct_id>NCT01555086</nct_id>
  </id_info>
  <brief_title>Prospective Study to Compare a Limited Versus Extended Pelvic Lymphadenectomy During Prostatectomy</brief_title>
  <acronym>SEAL</acronym>
  <official_title>Prospective Randomized Study to Compare a Limited Versus Extended Pelvic Lymphadenectomy During Prostatectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Association of Urologic Oncology (AUO)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Association of Urologic Oncology (AUO)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study examines Limited versus extended pelvic lymphadenectomy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is meant to show if the extension of lymphadenectomy during prostatectomy has an
      influence of outcome of patients. Patients with indication to prostatectomy due to prostate
      cancer will be included.

      Both extensions of lymphadenectomy are used in hospitals as a free choice. This study shell
      show if one method is more effective than the other.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2011</start_date>
  <primary_completion_date type="Anticipated">August 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PSA-progress</measure>
    <time_frame>5 years</time_frame>
    <description>3-monthly Follow-up with PSA-measurement in blood</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of overall survival</measure>
    <time_frame>5 years</time_frame>
    <description>Comparison of overall survival after limited versus extended lymphadenectomy after prostatectomy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of morbidity</measure>
    <time_frame>5 years</time_frame>
    <description>Comparison of morbidity after limited versus extended lymphadenectomy after prostatectomy</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Limited pelvic Lymphadenectomy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Extended pelvic Lymphadenectomy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Limited pelvic Lymphadenectomy</intervention_name>
    <description>approximately 10-14 lymph nodes are removed</description>
    <arm_group_label>Limited pelvic Lymphadenectomy</arm_group_label>
    <other_name>limited pelvic LA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Extended pelvic Lymphadenectomy</intervention_name>
    <description>approximately 20 lymph nodes are removed</description>
    <arm_group_label>Extended pelvic Lymphadenectomy</arm_group_label>
    <other_name>extended pelvic LA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  stamp bioptic secured prostate cancer with intermediate or high risk profile (defined
             as Gleason-Score 7-10 or PSA &gt; 10 ng/ml)

          -  locally-operable tumor according to DRU/TRUS

          -  negative bone scan

          -  negative CT abdomen / pelvis

          -  general condition according to Karnofsky &gt;/= 80%

          -  written consent of the patient

          -  adequate hematological, renal and coagulation physiological functions

          -  Patient compliance and geographic proximity to allow adequate follow-up

        Exclusion Criteria:

          -  Manifest secondary malignancy

          -  Secured metastasis by histologically or by imaging

          -  Myocardial infarction or stroke within the last 6 months

          -  Existing major cardiovascular (grade III - IV according to NYHA), pulmonary (pO2 &lt;60
             mmHg), renal, hepatic or hematopoietic (eg severe bone marrow aplasia) diseases

          -  Severe active or chronic infections (eg pos. HIV-Ab test, HBs-Ag detection in serum
             and / or chronic hepatitis)

          -  severe psychiatric disease

          -  prior chemotherapy (allowed is a preoperative antiandrogen therapy ≤ 3 months)

          -  previous pelvic radiotherapy

          -  Patients in a closed institution according to an authority or court decision

          -  People who are in a dependent relationship or working relationship with the sponsor or
             investigator

          -  simultaneous participation in another clinical trial
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Heidrun Rexer</last_name>
    <email>heidrun.rexer@meckevidence.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Axel Heidenreich, Prof. Dr.</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Krankenhaus Maria Hilf</name>
      <address>
        <city>Krefeld</city>
        <state>Dießemer Bruch 80</state>
        <zip>47805</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michel Kämper</last_name>
      <phone>02151 / 334-5248</phone>
      <email>M.Kaemper@alexianer.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Martiniklinik am UKE</name>
      <address>
        <city>Hamburg</city>
        <state>Martinistraße 52</state>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anneta Malamateniou</last_name>
      <phone>040/74 10 51 311</phone>
      <email>malamateniou@martini-klinik.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Antonius-Krankenhaus</name>
      <address>
        <city>Gronau</city>
        <state>Möllenweg 22</state>
        <zip>48599</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Günter Gust</last_name>
      <phone>02562/915-77 80</phone>
      <email>gust@st-antonius-gronau.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Städtisches Klinikum Fulda</name>
      <address>
        <city>Fulda</city>
        <state>Pacelliallee 3-5</state>
        <zip>36043</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthias Schieber, Dr.</last_name>
      <email>Matthias.Schieber@klinikum-fulda.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>RWTH Aachen</name>
      <address>
        <city>Aachen</city>
        <state>Pauwelsstraße 30</state>
        <zip>51074</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandra Richlowski</last_name>
      <phone>0241/80-35 358</phone>
      <email>srichlowski@ukaachen.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 13, 2012</study_first_submitted>
  <study_first_submitted_qc>March 14, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 15, 2012</study_first_posted>
  <last_update_submitted>January 23, 2017</last_update_submitted>
  <last_update_submitted_qc>January 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lymphadenectomy</keyword>
  <keyword>Prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

